BioPharma Dive October 23, 2024
A Yale spinout agreed to sell to Merck for $30 million upfront. Elsewhere, Roche reported strengthening demand for Sarepta’s Duchenne therapy, which it sells outside of the U.S.
Today, a brief rundown of news from Merck & Co. and Roche, as well as updates from Sangamo Therapeutics, UCB and Catalent that you may have missed.
Merck & Co. will pay $30 million upfront to acquire Modifi Biosciences, a Yale University spinout developing small molecule drugs for cancer. Founded in 2021, Modifi focuses on DNA repair defects in cancer cells, specifically one repair protein known as MGMT for short. Shareholders in Modifi could receive up to $1.3 billion in additional payments if certain, unspecified milestones are met. — Ned Pagliarulo
Sales...
Today's Sponsors
Today's Sponsor